Science 37 Stimulus Grant Reports Under Nasdaq Listing Rule 5635(c)(4)

Science 37 Stimulus Grant Reports Under Nasdaq Listing Rule 5635(c)(4)

Science 37, Inc
Science 37, Inc

RESEARCH TRIANGLE PARK, North Carolina, Nov. 10, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. today announced… (Nasdaq: SNCE), industry leader Metasite™, announced the grant of incentive stock awards under Science 37 Holdings, Inc. The 2022 Employment Incentive Award Plan (“Plan”) has been amended and restated. The plan was approved by Science 37’s Board of Directors in November 2023. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and are provided as a material incentive to non-executive employees. Entering into employment with the company.

In connection with the commencement of employment, on November 10, 2023, options to purchase an aggregate of 36,500 shares of Science 37 common stock at an exercise price of $0.2874 per share, which is the closing sale price of Science 37 common stock on the Nasdaq Market LLC were granted on the date of grant to two Of new employees.

The options have a term of 10 years and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining underlying shares vesting in equal monthly installments until they vest in full on the fourth anniversary of the grant date, subject to the continued service of the employee concerned with Science 37 through each applicable due date.

About science 37
The mission of Science 37 Holdings, Inc. is (Nasdaq: SNCE) is accelerating clinical research by enabling universal access to trials for patients. With Metasite™, we reach a larger population beyond the traditional site, achieving our goal of clinical research that works for everyone – with greater patient diversity. Patients have the flexibility to participate at their home, at a local community provider, or at a brick-and-mortar site when needed. Our Metasite is powered by a proprietary technology platform with in-house clinical and operational experts driving a standardized study format, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.

Cautionary note regarding forward-looking statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and the expected growth and profitability of Science 37. These forward-looking statements are generally identified by the words “we believe “, “can”, “could”, “seek”, “plan”, “anticipate”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “May”, “may”, “should”, “will”, “will”, “will continue”, “is likely to” and the like. Expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this press release, including but not limited to: (1) the ability to maintain the listing of Science 37’s securities on the Nasdaq Stock Market LLC, ( 2) Fluctuations in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, differences in performance across competitors, changes in laws and regulations affecting Science 37’s business, and changes in its capital structure and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (3) the ability to implement business plans, forecasts and other projections, and to identify and realize additional opportunities, (4) the risk that Science 37 may not never achieve or maintain profitability, (v) the risk that Science 37 will need to raise additional capital to implement its business plan, which may not be available on acceptable terms or at all, (vi) failure to achieve anticipated cost savings, and (vii) Risks related to the general economic and financial conditions of the market. The above list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (SEC). (“SEC”) on March 6, 2023 and in other documents that Science 37 files from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and Science 37 undertakes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Science 37 makes no guarantee that Science 37 will meet its expectations.

Media inquiries:
Grace Muhrin
Science 37
PR@science37.com

Investor Relations:
Steve Halper
LifeSci Consultants
investors@science37.com

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *